Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733546 · ClinicalTrials.gov registry record · Phase 2
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder, sponsored by COMPASS Pathways.
- Active
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 5
- Study locations
NCT05733546: Active Phase 2 study of Major Depressive Disorder, sponsored by COMPASS Pathways.
NCT05733546 is a Phase 2 study of Major Depressive Disorder that is active but no longer recruiting, run by COMPASS Pathways. The registered enrollment target is 102 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (73% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05733546, a Phase 2 study of Major Depressive Disorder, is active but no longer recruiting, sponsored by COMPASS Pathways.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 5
- Study locations
Study Summary
Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.
Primary Outcome
Proportion of patients with adverse events (AEs)
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (5)
California
- Kadima Neuropsychiatry Institute - La Jolla
Florida
- Clinical Neuroscience Solutions Inc - Jacksonville
Maryland
- Sunstone Therapies - Rockville
Massachusetts
- Elixia MA, LLC - Springfield
Texas
- Aims Trial - Plano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2025-09 |
| Phase | Phase 2 |
What the registry record for NCT05733546 still lists
NCT05733546 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT05733546 lists 5 locations in 5 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT05733546 about?
NCT05733546 is a clinical study titled "A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder". Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.
What is the current status of trial NCT05733546?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2023-01-30. Estimated completion is 2025-09.
What conditions does trial NCT05733546 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05733546?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05733546?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05733546 being conducted?
This trial has 5 study locations across California, Florida, Maryland, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05733546's enrollment target sits among peer trials
102 131st of 282 higher than 152 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI